The Vdr: Why Your Vitamin D3 Might Not Be Protecting Your Ageing Brain
Quick Read Vitamin D does more than support bones. It acts as a signalling molecule that switches genes on and
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
New blood tests can now detect early signs of brain stress by measuring tiny protein fragments released when brain cells are damaged. Four markers stand out: p-tau217 and p-tau181 (linked to Alzheimer’s plaques), GFAP (released by stressed brain support cells), and NfL (a general damage signal). P-tau217 appears most powerful for detecting Alzheimer’s-related changes years before symptoms appear.
However, these markers work best as a panel rather than individual tests, and they cannot diagnose disease on their own. Results need professional interpretation, and your metabolic health matters enormously. Vitamin D and B12 deficiencies, blood sugar problems, and chronic inflammation all affect these marker levels independently, so sorting out your basic health metrics first is essential before spending money on specialist brain tests.
If you choose to get tested, prioritise p-tau217 and GFAP, make sure your basic metabolic markers are in order, and use the results as a direction-pointer for further investigation rather than a final diagnosis. The real value comes from tracking changes over time rather than a single snapshot.
Verdict: Blood-based brain biomarkers are a real and advancing science useful for early warning, but they require proper context, professional interpretation, and metabolic baseline checks to be meaningful.
What if the most important thing you could do for your brain health this year wasn’t a supplement, a diet, or a meditation practice, but a simple blood test you could understand yourself? Most people think of brain health monitoring as something that happens after problems appear: a memory clinic referral, a brain scan, a spinal tap. But science is quietly rewriting that story. Right now, researchers are validating a handful of blood markers that can detect early signs of brain stress, sometimes years before any symptom appears. The question isn’t whether this science is real. It is. The question is: which markers actually matter, what do they tell you, and what should a sensible, informed person actually do with that information?
Vitacuity analysed over 1.77 million research papers and identified the most relevant science on this topic. What follows is the clearest, most honest summary we can give you, no hype, no false reassurance.
Here’s something remarkable: your brain is constantly communicating with the rest of your body through your bloodstream. When neurons are stressed, damaged, or dying, even at very low levels, they release tiny fragments of proteins into circulation. Until recently, detecting those fragments required either a lumbar puncture (spinal fluid extraction) or an expensive PET brain scan. Neither is practical for routine monitoring.
That’s changed. A new generation of ultra-sensitive blood tests can now detect these brain-derived proteins at vanishingly small concentrations. Four markers in particular have emerged from the research as the most clinically meaningful [2][6][7]:
– P-tau217 and P-tau181, phosphorylated forms of the tau protein, which accumulates in tangles inside neurons in Alzheimer’s disease – Amyloid-β 42/40 ratio (Aβ42/40), a ratio reflecting amyloid plaque formation, the other hallmark of Alzheimer’s pathology – GFAP (Glial Fibrillary Acidic Protein), released by stressed or damaged support cells (astrocytes) in the brain – NfL (Neurofilament Light Chain), a structural protein released when nerve fibres are damaged, a general marker of neurodegeneration
Think of these four as a dashboard. Each light tells you something slightly different about what’s happening under the bonnet. The art, and the limitation, is in reading them together, not individually.
Of all the brain blood markers studied, p-tau217 has emerged as the single most powerful signal for Alzheimer’s-related pathology. A major 2024 head-to-head comparison published in *Alzheimer’s & Dementia* tested blood tests from six leading commercial laboratories, C2N Diagnostics, Fujirebio, ALZPath, Janssen, Roche, and Quanterix, against PET brain scans in participants from the Alzheimer’s Disease Neuroimaging Initiative [7].
The finding was unambiguous: p-tau217 measures, alone or in combination with other markers, had the strongest relationships with all Alzheimer’s-related outcomes, amyloid PET, tau PET, cortical thickness, and dementia severity. Every commercial platform that measured p-tau217 outperformed those that didn’t [7].
Evidence grade: Strong, replicated across multiple large cohorts with head-to-head commercial comparison.
A separate 2025 study of 648 cognitively unimpaired adults (average age 69.9) found something particularly striking: elevated p-tau217 was exclusively associated with poorer episodic memory performance (β = -0.11, SE = 0.04, p = 0.003), even after accounting for NfL [14]. In other words, p-tau217 appears to specifically flag Alzheimer’s-related memory decline, not just general cognitive ageing. That specificity matters enormously if you want to understand *why* your memory might be changing.
A 2025 review in *Fortschritte der Neurologie-Psychiatrie* confirmed that p-tau217 is one of the most reliable markers for detecting Alzheimer’s pathology from its earliest stages, including the pre-symptomatic phase known as subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) [4]. The same review highlighted promising composite ratios like the “AT217-term”, which multiplies the amyloid ratio by p-tau217, as potentially offering even greater early-detection power [4].
GFAP is released by astrocytes, the brain’s support cells, when they are under stress or responding to injury. Think of it as a fire alarm going off in the scaffolding around your neurons.
A 2024 longitudinal study from the Baltimore Longitudinal Study of Aging followed 622 participants (mean age 70.9) with an average of 3.3 MRI scans over 4.7 years [15]. The findings: higher baseline GFAP was associated with greater increases in ventricular volume over time, in plain English, the brain’s fluid-filled spaces were expanding, a sign that surrounding brain tissue was shrinking [15].
In the same study, higher p-tau-181 predicted steeper declines in total grey matter and accelerated loss specifically in medial temporal regions, the memory centres of the brain [15].
A separate 2024 multimarker study (n = 1,199) developed a clinical interpretation tool using p-tau181, GFAP, and NfL together [6]. This combination achieved: – 83–89% accuracy in identifying amyloid positivity in pre-dementia stages – 87–89% accuracy in distinguishing Alzheimer’s from frontotemporal dementia – 74–76% accuracy in distinguishing Alzheimer’s from Lewy body dementia
The results were highly reproducible across two independent cohorts [6].
Evidence grade: Strong for GFAP as a marker of brain stress and neurodegeneration risk, particularly when used in combination with p-tau and NfL.
Neurofilament Light Chain (NfL) is the broadest of the four key markers. When nerve fibres are physically damaged, from any cause, they release NfL into the bloodstream.
The 2025 study of 648 cognitively unimpaired adults found that elevated NfL was non-specifically associated with poorer performance across a range of cognitive domains, language, processing speed, attention, and more, even after accounting for p-tau217 [14]. This contrasts sharply with p-tau217’s specificity for episodic memory. NfL is essentially saying “something is damaging neurons” without specifying what [14].
This distinction is clinically important. If your NfL is elevated but your p-tau217 is normal, the cause of any cognitive changes is likely not Alzheimer’s disease, it could be vascular, metabolic, inflammatory, or something else entirely [14]. NfL on its own is a flag that says “investigate further,” not a diagnosis.
The Baltimore Longitudinal Study noted that among cognitively unimpaired adults, NfL at baseline did *not* significantly predict future brain atrophy or cognitive decline, whereas p-tau181 and GFAP did [15]. This suggests NfL may be more useful as a real-time injury marker than a long-range predictive one.
Evidence grade: Strong for NfL as a general neurodegeneration marker; Promising for its predictive value in otherwise healthy individuals.
The ratio of two amyloid proteins, Aβ42 to Aβ40, is one of the most studied markers in Alzheimer’s research. When amyloid plaques are forming in the brain, Aβ42 is preferentially deposited there, so less of it circulates in the blood. A falling Aβ42/40 ratio therefore suggests amyloid accumulation may be occurring.
However, the 2024 head-to-head study found that plasma Aβ42/40 had relatively low accuracy in classifying amyloid status compared to p-tau217 [7]. This doesn’t mean the ratio is useless, when combined with p-tau217 in composite scores, accuracy improves, but on its own, it’s the weakest of the four main markers [7].
A 2019 cohort study (n = 107, followed every 6 months for 3 years) found that lower Aβ40 and Aβ42 were associated with greater cognitive decline on the Montreal Cognitive Assessment (MoCA) and Cambridge Cognitive Examination (CAMCOG) [10]. However, this was a smaller, retrospective study and the findings should be interpreted cautiously.
A 2025 review confirmed that the amyloid ratio remains valuable, particularly when used as part of a composite panel that includes p-tau and GFAP, and noted that newer variants such as the Aβ-3-42/-3-40 ratio may offer additional mechanistic insights into early amyloid processing [4].
Evidence grade: Promising as a standalone marker; Strong when incorporated into multi-marker panels alongside p-tau217.
Beyond the four core markers, researchers are increasingly interested in inflammatory signals in the blood, cytokines like IL-6, TNF-α, and IL-8, as potential early warning signs of brain stress.
The 2019 cohort study found that higher IL-8, IL-10, and TNF-α were associated with greater cognitive decline on both the MoCA and CAMCOG [10]. Higher MMP-3 (a protein involved in tissue remodelling) was elevated in subjective memory impairment, MCI, and probable Alzheimer’s compared to cognitively normal adults [10]. A composite score using amyloid, inflammatory, and MMP markers achieved a c-statistic of 0.732, compared to 0.602 for age and sex alone, in predicting a diagnosis of probable Alzheimer’s [10].
However, a 2025 consensus paper in the field issued important cautions [1][8]:
1. A single inflammatory marker is insufficient to characterise neuroinflammation, multiple markers should be measured simultaneously 2. Blood inflammatory marker changes cannot be used to infer neuroinflammatory mechanisms in the brain directly 3. Neuroinflammation shows time-dependent and disease-context-dependent patterns, the same marker can mean different things at different disease stages
Evidence grade: Promising for inflammatory panels as an adjunct to core markers; not yet ready for standalone clinical use.
Here’s something the standard “get a blood test” advice almost never mentions: the very markers you’re measuring can be affected by your nutritional status, metabolic health, and inflammation, independently of what’s happening in your brain.
A major 2025 review in *Frontiers in Aging Neuroscience* found that [3][11]:
– Deficiencies in vitamins E, D, and B12 contribute to oxidative stress and neuroinflammation, which in turn alter levels of Aβ, p-tau, and NfL in the blood – Chronic systemic inflammation from cytokines like IL-6, IL-18, and TNF-α is strongly linked to amyloid plaque formation and tau tangle accumulation – Insulin resistance, dyslipidaemia, and thyroid imbalance further alter biomarker levels and complicate interpretation
This creates a genuinely important practical point: if you are deficient in vitamin D or B12, or if you have uncontrolled blood sugar or thyroid issues, your brain biomarker results may be harder to interpret accurately [3][11]. Correcting these metabolic factors isn’t just good health practice, it may improve the signal-to-noise ratio of the very tests you’re trying to use.
The same review proposed that these three factors, nutrition, inflammation, and metabolic health, create a self-reinforcing cycle of neurodegeneration [3][11]. In other words, the markers aren’t just measuring brain disease; they’re also measuring how well the rest of your body is supporting your brain.
Evidence grade: Promising, based on review of epidemiological and biological evidence; causal directionality requires further human trials.
The clearest message from the 2025–2026 research is that single-marker testing is giving way to multi-marker panels [2][6].
A 2026 review in *Molecular Neurobiology* described a tiered approach emerging in memory clinics: genomic risk profiling (including APOE genotype) combined with a blood panel of Aβ42/40, p-tau217, GFAP, and NfL, used to identify who should proceed to confirmatory cerebrospinal fluid analysis or PET scanning [2]. A 2025 study measuring 18 distinct blood biomarkers in 125 participants confirmed that different markers provide complementary information across the spectrum of amyloid, tau, neurodegeneration, inflammation, and oxidative stress [5][13].
The vision isn’t one blood test that tells you everything. It’s a panel that tells you where to look next [2][6].
It’s important to be completely honest here, because this field is moving fast, and that means some things that look certain today may be refined tomorrow.
Reference ranges for healthy people are still being established. Most of the research on p-tau217, GFAP, and NfL has been conducted in people who are already cognitively impaired or at high clinical risk. What “normal” looks like across healthy adults of different ages, sexes, ethnicities, and metabolic health profiles is still being worked out [1][3].
Blood markers reflect but cannot prove brain disease. A 2025 consensus paper was explicit: association studies in humans cannot establish causal mechanisms, and blood marker changes cannot be used to directly infer what is happening in the brain’s own inflammatory or degenerative processes [1][8]. The markers are windows, not a direct view.
Many emerging markers are not ready for clinical use. Extracellular vesicle (EV) biomarkers and microRNA panels are biologically plausible and may detect brain changes before symptoms, but the datasets are small, mostly from single large cohorts (ADNI), and require standardised handling and external validation before they can be used in routine care [2][9].
Metabolic confounders are still being unravelled. The 2025 review on biological determinants of biomarker levels was clear: we don’t yet fully understand the synergistic interactions between nutritional status, inflammation, and metabolic disorders in shaping biomarker readings [3][11]. This means individual results need to be interpreted in context, not in isolation.
Inflammatory markers in particular need standardisation. The field lacks consensus on which inflammatory markers to measure, at what disease stage, using which assay, and how to compare results across laboratories [1][8]. Calling IL-6 or TNF-α a “brain health marker” on a standard blood panel is currently premature as a standalone tool.
So what should a sensible, informed person in their 40s, 50s, or 60s actually *do* with all this?
First, understand that this science is real and it’s maturing rapidly. Blood-based brain biomarkers are not fringe, they are being used in memory clinics today, and they will be standard practice within the next decade. Knowing what they measure puts you ahead of the curve.
Here’s the practical framework:
1. Sort your metabolic house first. Before spending money on specialist brain biomarker tests, make sure your vitamin D, B12, thyroid, fasting glucose, and HbA1c are all in a healthy range [3][11]. These are available on a standard NHS or private blood panel. Deficiencies in these markers not only affect brain health directly, they confound the specialist markers you’d be trying to read. This is low-cost, high-value.
On vitamins: B12 is water-soluble and excess is excreted, supplement daily if you’re over 50, as absorption declines with age. Vitamin D is fat-soluble but very hard to overdose at 1,000–4,000 IU. Given that the UK population is widely deficient, especially from October to April, supplementing confidently at this range is the sensible default. The risk of deficiency far outweighs the risk of supplementing.
2. If you’re accessing a private brain panel, prioritise p-tau217 and GFAP. These two markers have the strongest evidence for predicting future brain atrophy and cognitive decline in people who are currently symptom-free [7][14][15]. NfL adds value as a general injury signal. The Aβ42/40 ratio adds value in a composite panel but is weaker alone [7].
3. Don’t read a single marker in isolation. Elevated NfL without elevated p-tau217? That’s not Alzheimer’s pattern, it’s a signal to investigate other causes [14]. Elevated GFAP alongside elevated p-tau? That’s a more concerning combination that warrants medical follow-up [6][15]. Context matters enormously.
4. Use the results as a direction-pointer, not a diagnosis. None of these blood markers are diagnostic on their own. They are screening tools that tell you whether further investigation, with a neurologist, possibly including CSF or PET, is warranted [4][12]. Think of them as an early warning system, not a verdict.
5. Repeat over time. The real power of these markers is in tracking trends. A single snapshot is useful; serial measurements over two to three years are far more informative about the trajectory of your brain health [15].
6. Control what you can control. The 2025 review on biological determinants makes it clear: chronic inflammation, insulin resistance, and nutritional deficiencies don’t just confound your blood markers, they actively contribute to the neurodegeneration those markers are measuring [3][11]. Managing blood sugar, reducing systemic inflammation, ensuring adequate micronutrient intake, and maintaining a healthy weight aren’t just general wellness advice. In the context of brain biomarker science, they are evidence-based interventions.
The science of reading your blood for brain health is here. It’s not perfect yet, but it’s real, it’s improving, and it belongs in the hands of people who are serious about their cognitive future, not just their doctors.
[1] Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization. (2025). PubMed: https://pubmed.ncbi.nlm.nih.gov/40234920/
[2] Circulating Vesicular Biomarkers in Alzheimer’s Disease: From Mechanistic Insights to Clinical Applications. (2026). DOI: 10.1007/s12035-025-05634-6 | PubMed: https://pubmed.ncbi.nlm.nih.gov/41489760/
[3] Biological determinants of blood-based biomarker levels in Alzheimer’s disease: role of nutrition, inflammation, and metabolic factors. (2025). DOI: 10.3389/fnagi.2025.1614962 | PubMed: https://pubmed.ncbi.nlm.nih.gov/41280310/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12631643/
[4] News on blood biomarker-based early diagnosis of the preliminary stages of Alzheimer’s dementia. (2025). DOI: 10.1055/a-2698-5992 | PubMed: https://pubmed.ncbi.nlm.nih.gov/41197657/
[5] Blood biomarkers of amyloid and tau pathologies, brain degeneration, inflammation, and oxidative stress in early- and late-onset Alzheimer’s disease. (2025). DOI: 10.1177/13872877251340955 | PubMed: https://pubmed.ncbi.nlm.nih.gov/40336292/
[6] Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice. (2024). DOI: 10.1002/alz.14088 | PubMed: https://pubmed.ncbi.nlm.nih.gov/39096164/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497719/
[7] Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. (2024). DOI: 10.1002/alz.14315 | PubMed: https://pubmed.ncbi.nlm.nih.gov/39394841/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567821/
[8] Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization. (2025). PubMed: https://pubmed.ncbi.nlm.nih.gov/40234920/
[9] Circulating Vesicular Biomarkers in Alzheimer’s Disease: From Mechanistic Insights to Clinical Applications. (2026). DOI: 10.1007/s12035-025-05634-6 | PubMed: https://pubmed.ncbi.nlm.nih.gov/41489760/
[10] Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. (2019). DOI: 10.3233/JAD-180970 | PubMed: https://pubmed.ncbi.nlm.nih.gov/30636741/
[11] Biological determinants of blood-based biomarker levels in Alzheimer’s disease: role of nutrition, inflammation, and metabolic factors. (2025). DOI: 10.3389/fnagi.2025.1614962 | PubMed: https://pubmed.ncbi.nlm.nih.gov/41280310/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12631643/
[12] News on blood biomarker-based early diagnosis of the preliminary stages of Alzheimer’s dementia. (2025). DOI: 10.1055/a-2698-5992 | PubMed: https://pubmed.ncbi.nlm.nih.gov/41197657/
[13] Blood biomarkers of amyloid and tau pathologies, brain degeneration, inflammation, and oxidative stress in early- and late-onset Alzheimer’s disease. (2025). DOI: 10.1177/13872877251340955 | PubMed: https://pubmed.ncbi.nlm.nih.gov/40336292/
[14] Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits. (2025). DOI: 10.1002/alz.14619 | PubMed: https://pubmed.ncbi.nlm.nih.gov/40110626/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923558/
[15] Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline. (2024). DOI: 10.1186/s13195-024-01459-y | PubMed: https://pubmed.ncbi.nlm.nih.gov/38689358/ | PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11059745/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Vitamin D does more than support bones. It acts as a signalling molecule that switches genes on and
Quick Read Multiple large studies show that people who drink coffee regularly have lower rates of dementia and cognitive decline.
Free guide: The research behind brain health supplements
Plus our weekly research digest — straight to your inbox.
Just leave your email address.